The FDA Purple Book provides information regarding which category of products?

• A. Regulatory framework for marketing biologics
• B. Instructions for biosimilar naming conventions
• C. Information regarding biosimilar and interchangeable biological products approved under the Public Health Service Act
• D. Guidance on adverse event reporting for biologics

Answer: (C)

The FDA Purple Book catalogs biosimilar and interchangeable biological products that have been licensed under the Public Health Service Act. It’s the go-to resource for confirming which biologic products are approved as biosimilars and which have been designated as interchangeable with a reference product, along with related licensing details. This distinction is specific to biosimilars and interchangeable biologics and their regulatory status under the PHS Act, not to broader marketing frameworks, naming conventions, or adverse event reporting. So the Purple Book’s primary purpose is to provide information about those biosimilar and interchangeable products that have FDA approval under the Public Health Service Act.